Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 21, 2017

BD and Euroclone to develop tests for sexually transmitted pathogens

US-based firm Becton, Dickinson and Company (BD) and Italian diagnostic products maker Euroclone Diagnostica have entered an agreement for the development and global distribution of molecular tests to detect emerging sexually transmitted pathogens.

US-based firm Becton, Dickinson and Company (BD) and Italian diagnostic products maker Euroclone Diagnostica have entered an agreement for the development and global distribution of molecular tests to detect emerging sexually transmitted pathogens.

The molecular tests are expected to improve the potential for an accurate diagnosis and treatment in the presence or absence of symptoms.

In addition to supporting clinical laboratories for antimicrobial stewardship, the assays will help institutions to comply with European guidelines for sexually transmitted infections (STI) screening.

The new assays will run on the fully automated BD MAX System to detect infectious genital mycoplasmas such as Mycoplasma and Ureaplasma species that are difficult to diagnose using standard methods.

Lack of proper diagnosis and treatment of such infections are reported to result in immediate and long-term health consequences, including infertility and heightened HIV susceptibility.

"The new tests will be able to detect resistance markers of common drug therapies and allow prescription of a required course of antibiotic therapy."

The new tests will be able to detect resistance markers of common drug therapies and allow prescription of a required course of antibiotic therapy.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

BD Women’s Health and Molecular Diagnostics vice-president Doug White said: “BD and Euroclone share a passion for reducing the risks associated with undiagnosed STIs, as well as the burden of symptoms that impact the lives of many worldwide.”

The new molecular assays will expand the firm’s current BD MAX portfolio, which includes the BD SurePath liquid-based Pap test and BD Onclarity HPV assay for identification of 14 high-risk HPV genotypes.

The firms intend to initiate commercialisation of the tests outside of the US next year, with plans to later expand the launch to the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU